Overview
DDI Between BI Empagliflozin (10773) and Verapamil
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Relative bioavailability of BI 10773 given alone and together with verapamilPhase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Boehringer IngelheimTreatments:
Empagliflozin
Verapamil
Criteria
Inclusion criteria:healthy male and female subjects
Exclusion criteria:
Any relevant deviation from healthy conditions